Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 8 (2011), Issue 1 (January)

1. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
   Int J Radiat Oncol Biol Phys, 79(2): 549-58. [Abstract] [Full-text]
2. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
   Int J Radiat Oncol Biol Phys, 79(2): 363-70. [Abstract] [Full-text]
3. α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues.
   Urology, 77(1): 249.e1-7. [Abstract] [Full-text]
4. Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group.
   Urology, 77(1): 149-53. [Abstract] [Full-text]
5. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
   Cancer Lett, 301(1): 17-28. [Abstract] [Full-text]
6. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
   Int J Radiat Oncol Biol Phys, 79(2): 335-41. [Abstract] [Full-text]
7. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
   Int J Radiat Oncol Biol Phys, 79(2): 609-15. [Abstract] [Full-text]
8. PCA3: from basic molecular science to the clinical lab.
   Cancer Lett, 301(1): 1-6. [Abstract] [Full-text]
9. Trans-rectal ultrasound-coupled spectral optical tomography of total hemoglobin concentration enhances assessment of the laterality and progression of a transmissible venereal tumor in canine prostate.
   Urology, 77(1): 237-42. [Abstract] [Full-text]
10. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.
    Int J Radiat Oncol Biol Phys, 79(2): 616-22. [Abstract] [Full-text]
11. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.
    Int J Radiat Oncol Biol Phys, 79(2): 623-32. [Abstract] [Full-text]
12. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 79(2): 379-84. [Abstract] [Full-text]
13. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 371-8. [Abstract] [Full-text]
14. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Int J Radiat Oncol Biol Phys, 79(2): 385-91. [Abstract] [Full-text]
15. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.
    J Cancer Res Clin Oncol, 137(1): 19-28. [Abstract] [Full-text]
16. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids.
    Cancer Chemother Pharmacol, 67(1): 117-26. [Abstract] [Full-text]
17. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Int J Radiat Oncol Biol Phys, 79(2): 549-58. [Abstract] [Full-text]
18. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 363-70. [Abstract] [Full-text]
19. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Cancer Lett, 301(1): 17-28. [Abstract] [Full-text]
20. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(2): 335-41. [Abstract] [Full-text]
21. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
    Int J Radiat Oncol Biol Phys, 79(2): 609-15. [Abstract] [Full-text]
22. PCA3: from basic molecular science to the clinical lab.
    Cancer Lett, 301(1): 1-6. [Abstract] [Full-text]
23. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Exp Mol Pathol, 90(1): 97-100. [Abstract] [Full-text]
24. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.
    Int J Radiat Oncol Biol Phys, 79(2): 616-22. [Abstract] [Full-text]
25. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.
    Int J Radiat Oncol Biol Phys, 79(2): 623-32. [Abstract] [Full-text]
26. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 79(2): 379-84. [Abstract] [Full-text]
27. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 371-8. [Abstract] [Full-text]
28. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Int J Radiat Oncol Biol Phys, 79(2): 385-91. [Abstract] [Full-text]
29. Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo.
    Int J Radiat Oncol Biol Phys, 79(2): 549-58. [Abstract] [Full-text]
30. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 363-70. [Abstract] [Full-text]
31. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells.
    Cancer Lett, 301(1): 17-28. [Abstract] [Full-text]
32. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 79(2): 335-41. [Abstract] [Full-text]
33. Clinical trials of a urethral dose measurement system in brachytherapy using scintillation detectors.
    Int J Radiat Oncol Biol Phys, 79(2): 609-15. [Abstract] [Full-text]
34. PCA3: from basic molecular science to the clinical lab.
    Cancer Lett, 301(1): 1-6. [Abstract] [Full-text]
35. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population.
    Exp Mol Pathol, 90(1): 97-100. [Abstract] [Full-text]
36. Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.
    Int J Radiat Oncol Biol Phys, 79(2): 616-22. [Abstract] [Full-text]
37. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.
    Int J Radiat Oncol Biol Phys, 79(2): 623-32. [Abstract] [Full-text]
38. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 79(2): 379-84. [Abstract] [Full-text]
39. 3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.
    Int J Radiat Oncol Biol Phys, 79(2): 371-8. [Abstract] [Full-text]
40. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Int J Radiat Oncol Biol Phys, 79(2): 385-91. [Abstract] [Full-text]
41. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Int J Cancer, 128(5): 1232-9. [Abstract] [Full-text]
42. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Int J Cancer, 128(5): 1232-9. [Abstract] [Full-text]
43. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
    Int J Cancer, 128(5): 1232-9. [Abstract] [Full-text]
44. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.
    J Clin Endocrinol Metab, 96(1): E135-40. [Abstract] [Full-text]
45. Impact of age at diagnosis on prostate cancer treatment and survival.
    J Clin Oncol, 29(2): 235-41. [Abstract] [Full-text]
46. Outcomes of active surveillance for men with intermediate-risk prostate cancer.
    J Clin Oncol, 29(2): 228-34. [Abstract] [Full-text]
47. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo.
    Proc Natl Acad Sci U S A, 108(2): 704-9. [Abstract] [Full-text]
48. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
    Mol Carcinog, 50(2): 100-12. [Abstract] [Full-text]
49. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
    J Urol, 185(2): 706-11. [Abstract] [Full-text]
50. Single focus prostate cancer: pathological features and ERG fusion status.
    J Urol, 185(2): 489-94. [Abstract] [Full-text]
51. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    J Urol, 185(2): 477-82. [Abstract] [Full-text]
52. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
    J Urol, 185(2): 495-500. [Abstract] [Full-text]
53. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    J Urol, 185(2): 471-6. [Abstract] [Full-text]
54. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
    J Urol, 185(2): 483-7. [Abstract] [Full-text]
55. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.
    Oncogene, 30(2): 142-52. [Abstract] [Full-text]
56. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
    Oncogene, 30(2): 167-77. [Abstract] [Full-text]
57. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
    Mol Carcinog, 50(2): 100-12. [Abstract] [Full-text]
58. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
    J Urol, 185(2): 706-11. [Abstract] [Full-text]
59. Single focus prostate cancer: pathological features and ERG fusion status.
    J Urol, 185(2): 489-94. [Abstract] [Full-text]
60. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
    J Urol, 185(2): 477-82. [Abstract] [Full-text]
61. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy.
    J Urol, 185(2): 495-500. [Abstract] [Full-text]
62. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    J Urol, 185(2): 471-6. [Abstract] [Full-text]
63. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
    J Urol, 185(2): 483-7. [Abstract] [Full-text]
64. Synergistic antimicrotubule therapy for prostate cancer.
    Biochem Pharmacol, 81(4): 478-87. [Abstract] [Full-text]
65. Synergistic antimicrotubule therapy for prostate cancer.
    Biochem Pharmacol, 81(4): 478-87. [Abstract] [Full-text]
66. Low-grade fibromyxoid sarcoma metastatic to the prostate.
    Ann Diagn Pathol, 15(1): 64-8. [Abstract] [Full-text]
67. Synergistic antimicrotubule therapy for prostate cancer.
    Biochem Pharmacol, 81(4): 478-87. [Abstract] [Full-text]
68. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    J Pharmacol Exp Ther, 336(2): 496-505. [Abstract] [Full-text]
69. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
    Prostate, 71(3): 326-31. [Abstract] [Full-text]
70. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.
    Prostate, 71(3): 305-17. [Abstract] [Full-text]
71. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Prostate, 71(3): 281-8. [Abstract] [Full-text]
72. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
    Prostate, 71(3): 318-25. [Abstract] [Full-text]
73. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).
    Prostate, 71(3): 268-80. [Abstract] [Full-text]
74. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study.
    Prostate, 71(3): 225-31. [Abstract] [Full-text]
75. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.
    Prostate, 71(3): 298-304. [Abstract] [Full-text]
76. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.
    Prostate, 71(3): 232-40. [Abstract] [Full-text]
77. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence.
    Cancer Immunol Immunother, 60(2): 217-26. [Abstract] [Full-text]
78. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
    Cancer Immunol Immunother, 60(2): 197-206. [Abstract] [Full-text]
79. Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis.
    Cancer Immunol Immunother, 60(2): 187-95. [Abstract] [Full-text]
80. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
    Prostate, 71(4): 421-30. [Abstract] [Full-text]
81. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
    Prostate, 71(4): 415-20. [Abstract] [Full-text]
82. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
    Prostate, 71(4): 394-402. [Abstract] [Full-text]
83. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
    Prostate, 71(4): 431-7. [Abstract] [Full-text]
84. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
    Prostate, 71(4): 403-14. [Abstract] [Full-text]
85. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
    Prostate, 71(3): 326-31. [Abstract] [Full-text]
86. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.
    Prostate, 71(4): 344-52. [Abstract] [Full-text]
87. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
    Prostate, 71(4): 368-72. [Abstract] [Full-text]
88. Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
    Prostate, 71(4): 353-67. [Abstract] [Full-text]
89. Tumor cell group via phospholipase A₂ is involved in prostate cancer development.
    Prostate, 71(4): 373-84. [Abstract] [Full-text]
90. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
    Prostate, 71(4): 385-93. [Abstract] [Full-text]
91. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.
    Prostate, 71(3): 305-17. [Abstract] [Full-text]
92. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
    Prostate, 71(3): 281-8. [Abstract] [Full-text]
93. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
    Prostate, 71(4): 333-43. [Abstract] [Full-text]
94. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
    Prostate, 71(3): 318-25. [Abstract] [Full-text]
95. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).
    Prostate, 71(3): 268-80. [Abstract] [Full-text]
96. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study.
    Prostate, 71(3): 225-31. [Abstract] [Full-text]
97. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.
    Prostate, 71(3): 298-304. [Abstract] [Full-text]
98. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.
    Prostate, 71(3): 232-40. [Abstract] [Full-text]
99. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
    Prostate, 71(4): 421-30. [Abstract] [Full-text]
100. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
     Prostate, 71(4): 415-20. [Abstract] [Full-text]
101. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
     Prostate, 71(4): 394-402. [Abstract] [Full-text]
102. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
     Prostate, 71(4): 431-7. [Abstract] [Full-text]
103. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
     Prostate, 71(4): 403-14. [Abstract] [Full-text]
104. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
     Prostate, 71(3): 326-31. [Abstract] [Full-text]
105. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.
     Prostate, 71(4): 344-52. [Abstract] [Full-text]
106. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
     Prostate, 71(4): 368-72. [Abstract] [Full-text]
107. Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
     Prostate, 71(4): 353-67. [Abstract] [Full-text]
108. Tumor cell group via phospholipase A₂ is involved in prostate cancer development.
     Prostate, 71(4): 373-84. [Abstract] [Full-text]
109. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
     Prostate, 71(4): 385-93. [Abstract] [Full-text]
110. Expression of pleiotrophin in the prostate is androgen regulated and it functions as an autocrine regulator of mesenchyme and cancer associated fibroblasts and as a paracrine regulator of epithelia.
     Prostate, 71(3): 305-17. [Abstract] [Full-text]
111. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
     Prostate, 71(3): 281-8. [Abstract] [Full-text]
112. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
     Prostate, 71(4): 333-43. [Abstract] [Full-text]
113. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior.
     Prostate, 71(3): 318-25. [Abstract] [Full-text]
114. Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).
     Prostate, 71(3): 268-80. [Abstract] [Full-text]
115. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study.
     Prostate, 71(3): 225-31. [Abstract] [Full-text]
116. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells.
     Prostate, 71(3): 298-304. [Abstract] [Full-text]
117. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy.
     Prostate, 71(3): 232-40. [Abstract] [Full-text]
118. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.
     Prostate, 71(4): 421-30. [Abstract] [Full-text]
119. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.
     Prostate, 71(4): 415-20. [Abstract] [Full-text]
120. Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination.
     Prostate, 71(4): 394-402. [Abstract] [Full-text]
121. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer.
     Prostate, 71(4): 431-7. [Abstract] [Full-text]
122. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells.
     Prostate, 71(4): 403-14. [Abstract] [Full-text]
123. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes.
     Prostate, 71(4): 344-52. [Abstract] [Full-text]
124. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients.
     Prostate, 71(4): 368-72. [Abstract] [Full-text]
125. Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells.
     Prostate, 71(4): 353-67. [Abstract] [Full-text]
126. Tumor cell group via phospholipase A₂ is involved in prostate cancer development.
     Prostate, 71(4): 373-84. [Abstract] [Full-text]
127. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer.
     Prostate, 71(4): 385-93. [Abstract] [Full-text]
128. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
     Prostate, 71(4): 333-43. [Abstract] [Full-text]
129. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy.
     AJR Am J Roentgenol, 196(2): 374-81. [Abstract] [Full-text]
130. Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.
     J Biol Chem, 286(4): 2681-8. [Abstract] [Full-text]
131. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
     BJU Int, 107(3): 383-8. [Abstract] [Full-text]
132. High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy.
     BJU Int, 107(3): 378-82. [Abstract] [Full-text]
133. Testosterone augments polyphenol-induced DNA damage response in prostate cancer cell line, LNCaP.
     Cancer Sci, 102(2): 468-71. [Abstract] [Full-text]
134. Influence of caspases 8 and 9 gene promoter polymorphism on prostate cancer susceptibility and early development of hormone refractory prostate cancer.
     BJU Int, 107(3): 471-6. [Abstract] [Full-text]
135. Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer.
     BJU Int, 107(3): 486-92. [Abstract] [Full-text]
136. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.
     BJU Int, 107(3): 466-70. [Abstract] [Full-text]
137. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis.
     BJU Int, 107(3): 389-95. [Abstract] [Full-text]
138. 'LESS' radical prostatectomy: a pilot feasibility study with a personal original technique.
     BJU Int, 107(3): 460-4. [Abstract] [Full-text]
139. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
     BJU Int, 107(3): 477-85. [Abstract] [Full-text]
140. ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer.
     Am J Clin Oncol, 34(1): 92-8. [Abstract] [Full-text]
141. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
     J Nucl Med, 52(2): 270-8. [Abstract] [Full-text]
142. Evaluation of kV cone-beam ct performance for prostate IGRT: a comparison of automatic grey-value alignment to implanted fiducial-marker alignment.
     Am J Clin Oncol, 34(1): 16-21. [Abstract] [Full-text]
143. Androgen deprivation induces rapid involution and recovery of human prostate vasculature.
     Am J Physiol Endocrinol Metab, 300(2): E263-75. [Abstract] [Full-text]
144. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer.
     Am J Clin Oncol, 34(1): 11-5. [Abstract] [Full-text]
145. Acute toxicity after cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer.
     Am J Clin Oncol, 34(1): 6-10. [Abstract] [Full-text]
146. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?
     J Clin Oncol, 29(4): 464-7. [Abstract] [Full-text]
147. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.
     Biochem Biophys Res Commun, 404(4): 915-21. [Abstract] [Full-text]
148. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity.
     Biochem Biophys Res Commun, 404(4): 903-9. [Abstract] [Full-text]
149. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.
     J Clin Oncol, 29(4): 362-8. [Abstract] [Full-text]
150. Comorbidity and mortality results from a randomized prostate cancer screening trial.
     J Clin Oncol, 29(4): 355-61. [Abstract] [Full-text]
151. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
     Int J Cancer, 128(6): 1442-8. [Abstract] [Full-text]
152. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
     Int J Cancer, 128(6): 1462-70. [Abstract] [Full-text]
153. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
     Int J Cancer, 128(6): 1486-92. [Abstract] [Full-text]
154. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
     Int J Cancer, 128(6): 1414-24. [Abstract] [Full-text]
155. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
     Cancer Treat Rev, 37(2): 89-96. [Abstract] [Full-text]
156. Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.
     Int J Cancer, 128(7): 1697-702. [Abstract] [Full-text]
157. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
     Int J Cancer, 128(6): 1442-8. [Abstract] [Full-text]
158. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
     Int J Cancer, 128(6): 1462-70. [Abstract] [Full-text]
159. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
     Int J Cancer, 128(6): 1486-92. [Abstract] [Full-text]
160. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
     Int J Cancer, 128(6): 1414-24. [Abstract] [Full-text]
161. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
     Cancer Treat Rev, 37(2): 89-96. [Abstract] [Full-text]
162. Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.
     Int J Cancer, 128(7): 1697-702. [Abstract] [Full-text]
163. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
     Int J Cancer, 128(6): 1442-8. [Abstract] [Full-text]
164. PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.
     Int J Cancer, 128(6): 1462-70. [Abstract] [Full-text]
165. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
     Int J Cancer, 128(6): 1486-92. [Abstract] [Full-text]
166. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.
     Int J Cancer, 128(6): 1414-24. [Abstract] [Full-text]
167. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
     Cancer Treat Rev, 37(2): 89-96. [Abstract] [Full-text]
168. Surgery confounds biology: the predictive value of stage-, grade- and prostate-specific antigen for recurrence after radical prostatectomy as a function of surgeon experience.
     Int J Cancer, 128(7): 1697-702. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.